Cumberland Pharmaceuticals (NASDAQ:CPIX) Rating Increased to Buy at Wall Street Zen

Cumberland Pharmaceuticals (NASDAQ:CPIX) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cumberland Pharmaceuticals currently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Trading Down 1.6%

NASDAQ:CPIX opened at $3.04 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.01 and a debt-to-equity ratio of 0.21. Cumberland Pharmaceuticals has a 1-year low of $1.85 and a 1-year high of $6.26. The firm has a market capitalization of $45.48 million, a price-to-earnings ratio of -16.00 and a beta of -0.58. The stock has a fifty day simple moving average of $4.06 and a 200 day simple moving average of $3.43.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of large investors have recently made changes to their positions in CPIX. Heron Bay Capital Management acquired a new stake in shares of Cumberland Pharmaceuticals during the second quarter worth approximately $111,000. Two Sigma Investments LP grew its position in Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares in the last quarter. Marshall Wace LLP acquired a new position in Cumberland Pharmaceuticals in the 4th quarter valued at approximately $192,000. Perceptive Advisors LLC acquired a new position in Cumberland Pharmaceuticals in the 4th quarter valued at approximately $1,358,000. Finally, Dimensional Fund Advisors LP lifted its position in Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after buying an additional 27,980 shares in the last quarter. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.